Neurocrine presents new two-year Crenessity data

San Diego, USA-based Neurocrine Biosciences (Nasdaq: NBIX) has announced the first presentation of new two-year data from the Phase III CAHtalyst adult study demonstrating sustained, substantial reductions in glucocorticoid (GC) doses in adults with classic congenital adrenal hyperplasia treated with Crenessity (crinecerfont), with around 70% of patients achieving GC doses within the physiologic range.

Chronic exposure to supraphysiologic GC doses is associated with cardiometabolic comorbidities, bone density reductions, mental health issues and other long-term health risks that contribute to the cumulative treatment burden faced by patients over their lifetimes. Reducing high-dose, long-term GC exposure represents one of the most important goals in the management of classic congenital adrenal hyperplasia (CAH).